Engineering Magnesium Oxide as a Mitochondrial Electron Transport Chain Inhibitor for Enhanced Photodynamic Therapy in Triple-Negative Breast Cancer
Molecular Pharmaceutics · 04.08.2025 · 22 (8) · 5007-5020
DOI: 10.1021/acs.molpharmaceut.5c00671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 09.07.2025. Verfasst von Liang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 210009, China. Hauptthemen laut MEDLINE: Photochemotherapy, Triple Negative Breast Neoplasms, Mitochondria, Magnesium Oxide. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Jiangsu Provincial Department of Human Resources and Social Security.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited therapeutic options due to its resistance to conventional targeted therapies. TNBC cells heavily rely on oxidative phosphorylation (OXPHOS), making mitochondrial electron transport chain (ETC) inhibition a promising therapeutic approach. However, existing ETC inhibitors pose severe cytotoxicity risks, highlighting the need for biocompatible alternatives. In this study, we develop an MgO-ICG suspension (MgO-ICG@S), utilizing magnesium oxide (MgO), biocompatible pharmaceutical excipients that are already in widespread use as both an ETC-blocking agent and a drug carrier for the photosensitizer indocyanine green (ICG). This approach enables a bidirectional ETC blockade by disrupting ETC electronic transmission and functionality while inducing a unique mitochondria-targeted drug delivery effect. Additionally, laser irradiation activates ICG, generating reactive oxygen species (ROS) that further sensitize tumor cells to ETC inhibition. The combination of ETC blockade and photodynamic therapy (PDT) creates a synergistic cycle of oxidative damage, amplifying antitumor effects and significantly improving therapeutic outcomes. This study offers a promising strategy for effective, targeted TNBC treatment and provides valuable insights into the development of biocompatible ETC-blocking agents for clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 210009, China.
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 321 Zhongshan Road, Nanjing 210008, China.
ORCID-Profile: Hui Xiong
Förderung
- Jiangsu Provincial Department of Human Resources and Social Security
Zitieren
APA
Zhang, L., Wang, T., Shan, Y., Zhang, W., Yao, J., & Xiong, H. (2025). Engineering Magnesium Oxide as a Mitochondrial Electron Transport Chain Inhibitor for Enhanced Photodynamic Therapy in Triple-Negative Breast Cancer. Molecular Pharmaceutics, 22(8), 5007-5020. https://doi.org/10.1021/acs.molpharmaceut.5c00671
Vancouver
Zhang L, Wang T, Shan Y, Zhang W, Yao J, Xiong H. Engineering Magnesium Oxide as a Mitochondrial Electron Transport Chain Inhibitor for Enhanced Photodynamic Therapy in Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2025;22(8):5007-5020. doi:10.1021/acs.molpharmaceut.5c00671
BibTeX
@article{Zhang2025,
author = {Zhang, Liang and Wang, Ting and Shan, Yunyi and Zhang, Weijie and Yao, Jing and Xiong, Hui},
title = {Engineering Magnesium Oxide as a Mitochondrial Electron Transport Chain Inhibitor for Enhanced Photodynamic Therapy in Triple-Negative Breast Cancer},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {8},
pages = {5007--5020},
doi = {10.1021/acs.molpharmaceut.5c00671}
}
EUVIMED